The Technical Analyst
Translate Bio Inc [TBIO]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Translate Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-15.02% $0.331
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.96 mill |
| EPS: | -1.640 |
| P/E: | -0.200 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 30.10 mill |
| Avg Daily Volume: | 0.772 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.200 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.200 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.267 - 0.395 ( +/- 19.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-22 | Nelson Todd Robert | Buy | 385 500 | Stock Option (right to buy) |
| 2023-06-22 | Nelson Todd Robert | Buy | 47 700 | Common Stock |
| 2024-03-01 | Nelson Todd Robert | Sell | 4 756 | Common Stock |
| 2023-06-22 | Esser Eric Eugene | Buy | 263 600 | Stock Option (right to buy) |
| 2023-06-22 | Esser Eric Eugene | Buy | 32 600 | Common Stock |
| INSIDER POWER |
|---|
| 93.60 |
| Last 88 transactions |
| Buy: 85 227 522 | Sell: 75 433 698 |
Forecast:
16:00 - $0.331
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.331
Forecast 2: 16:00 - $0.331
Forecast 3: 16:00 - $0.331
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.331 (-15.02% ) |
| Volume | 0.251 mill |
| Avg. Vol. | 0.772 mill |
| % of Avg. Vol | 32.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TBIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TBIO
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-18 09:00:00 - Press Release
Telesis Bio Inc. Announces Strategic Focus On Game-changing Gibson Sola Enzymatic Dna Synthesis (eds) Platform And Bioxp Mrna Solutions And Announces New Leadership
San diego, april 18, 2024 (globe newswire) -- telesis bio inc. (nasdaq: tbio), a leader in automated benchtop dna and mrna synthesis solutions, today announced a focus in strategy enabled by the commercial availability of its groundbreaking gibson sola platform. going forward, the company will increasingly concentrate its efforts on expanding the adoption of gibson sola for both dna and mrna high throughput drug discovery applications and will specifically target the bioxp automation platform on mrna synthesis, where the company believes it has a highly differentiated offering with significant advantages over existing solutions.
2024-03-28 16:05:00 - Press Release
Telesis Bio Reports Fourth Quarter And Full Year 2023 Financial Results
San diego, march 28, 2024 (globe newswire) -- telesis bio inc. (nasdaq: tbio), a leading provider of rna and dna solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended december 31, 2023. results highlight strong bioxp® kit sales, expanding gross margin and reduced operating expense.
2024-02-26 09:15:00 - Press Release
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
San diego, feb. 26, 2024 (globe newswire) -- telesis bio inc. (nasdaq: tbio), a leading provider of rna and dna solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible and rapid automated synthesis in their own lab, today announced certain preliminary, unaudited financial results for the fourth quarter and year ended december 31, 2023. the results are subject to the completion of the company's year-end financial reporting processes, reviews, and audit.
2023-11-13 16:22:00 - Press Release
Telesis Bio Reports Third Quarter 2023 Financial Results
San diego, nov. 13, 2023 (globe newswire) -- telesis bio inc. (nasdaq: tbio), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023.
2023-11-07 09:00:00 - Press Release
Telesis Bio To Report Third Quarter Financial Results On Monday, November 13, 2023
San diego, nov. 07, 2023 (globe newswire) -- telesis bio (nasdaq: tbio), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on monday, november 13, 2023, after the market closes.
Latest News
2024-02-23 08:44:16 - InvestorPlace
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with some 7.4 million shares changing hands as of this writing.
2023-08-03 17:00:00 - GlobeNewsWire
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
2023-06-08 09:05:00 - GlobeNewsWire
Telesis Bio to Present at Jefferies Healthcare Conference 2023
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.
2023-06-06 03:00:00 - GlobeNewsWire
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery
2023-05-23 09:00:00 - GlobeNewsWire
Telesis Bio to Present at SynBioBeta 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery
2023-05-15 09:00:00 - GlobeNewsWire
Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)
Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications
2023-05-11 19:02:44 - Zacks Investment Research
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.
2023-04-27 16:05:00 - GlobeNewsWire
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, May 11, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
2023-03-25 10:28:04 - Seeking Alpha
Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conference Call Participants Brandon Couillard - Jefferies Harrison Schrage - KeyBanc Capital Markets Poon Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to the Q4 2022 Telesis Bio Earnings Conference Call. [Operator Instructions].
2023-03-21 19:04:54 - Zacks Investment Research
Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates
Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?